Viking Therapeutics Emerges as Key Player in Weight-Loss Drug Market
Published on 10/04/2025 at 07:00 | Redaktion boerse-global.de
Viking Therapeutics has captured significant market attention with its recent stock performance, demonstrating strong upward momentum following analyst confirmation of what they describe as a “substantial price surge.” The biopharmaceutical company’s shares closed at $27.88 on Thursday, marking a solid 1.86 percent gain.
The company’s metabolic disorder pipeline is generating considerable excitement, particularly its lead obesity candidate VK2735. Recent corporate updates from October 1 revealed important developmental milestones. The Phase 3 VANQUISH registration program for the injectable formulation is already underway, while the Phase 2 VENTURE trial for an oral tablet version has successfully achieved its primary endpoint.
This dual-approach strategy—offering both injectable and oral formulations—positions Viking competitively in the rapidly expanding weight-loss medication sector. Further expanding its metabolic portfolio,... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
